Retatrutide vs Tirzepatide: Which Should UK Researchers Choose in 2026?
Retatrutide and tirzepatide are the two incretin-based peptides UK researchers ask us about most. Both are Eli Lilly molecules and both target the incretin system, but they sit at very different stages of development and suit different research questions. This guide is a practical decision aid for 2026. For the detailed science, read our in-depth Tirzepatide vs Retatrutide research comparison.
Quick summary: Choose tirzepatide if you need a well-characterised dual GIP/GLP-1 reference compound with a large published evidence base and a lower price per mg. Choose retatrutide if your work focuses on the newer triple-agonist mechanism (GIP, GLP-1 and glucagon) and next-generation compounds. Many groups study both side by side.
The Key Differences in One Table
| Tirzepatide | Retatrutide | |
|---|---|---|
| Receptor targets | GIP + GLP-1 (dual agonist) | GIP + GLP-1 + glucagon (triple agonist) |
| Developer | Eli Lilly | Eli Lilly |
| Development stage | Approved medicine (as Mounjaro) | Investigational, Phase 3 (TRIUMPH) |
| Published evidence | Large: SURPASS and SURMOUNT programmes | Growing: Phase 2 published, Phase 3 reporting |
| Main research use | Reference dual agonist, benchmark comparisons | Triple-agonist and glucagon-pathway research |
| Revial Labs vial sizes | 20mg, 30mg | 10mg, 20mg, 30mg |
Mechanism: Dual vs Triple Agonist
Tirzepatide activates the GIP and GLP-1 receptors. Both are incretin hormones involved in insulin secretion, appetite signalling and gastric emptying.
Retatrutide adds a third target: the glucagon receptor. Glucagon signalling is linked to energy expenditure and liver fat metabolism, which is why the glucagon component is the main focus of retatrutide research. It is also why retatrutide is often described as the next step after dual agonists. See Triple Agonists: The Next Frontier.
Evidence Maturity
This is where the two differ most in 2026.
- Tirzepatide has completed large Phase 3 programmes. In SURMOUNT-1, published in the New England Journal of Medicine in 2022, participants in the top study arm recorded a mean body-weight reduction of around 21% over 72 weeks. It is now licensed in the UK as Mounjaro. That depth of data makes it a strong reference compound.
- Retatrutide reported Phase 2 results in 2023 (NEJM), where the top study arm recorded a mean reduction of around 24% at 48 weeks. Phase 3 TRIUMPH data is now emerging; see our summary of the TRIUMPH results. It is not yet approved anywhere.
Trial outcomes describe clinical study populations under medical supervision. They are included here as research context only.
Which Is Right for Your Research?
Choose tirzepatide if:
- You need a well-documented dual agonist as a control or benchmark
- Your work focuses on GIP and GLP-1 signalling specifically
- Cost per mg is a priority for larger studies
- You want to compare against an approved molecule
Choose retatrutide if:
- Your research question involves glucagon receptor activity
- You are studying next-generation multi-agonists
- You want to compare triple agonism against dual or single agonists
- Your work tracks the TRIUMPH programme and newer compounds such as survodutide and mazdutide
Choose both if:
You are running comparative work. Studying retatrutide against tirzepatide isolates the contribution of the glucagon component, which is one of the most active questions in the field.
Handling and Storage
Both peptides are supplied lyophilised and handled the same way: store powder at 2–8°C, reconstitute in bacteriostatic water, keep the solution refrigerated and use within about four weeks. See how to store peptides and use the Peptide Reconstitution Calculator for concentrations.
Quality Checks Apply to Both
Whichever you choose, insist on a batch-specific Certificate of Analysis with HPLC purity and mass spectrometry, ideally from an independent lab. Our certificates are on the Lab Results page, and why COA testing matters explains what to look for.
Related Research Guides
Explore our other UK research guides:
- BPC-157 UK: The Complete Research Guide
- TB-500 UK: The Complete Research Guide
- Wolverine Blend Explained: BPC-157 + TB-500
- KLOW vs GLOW Blends Explained
- GHK-Cu UK: The Complete Research Guide
- MOTS-c UK: The Complete Research Guide
- NAD+ UK: The Complete Research Guide
- Free Peptide Reconstitution Calculator
Frequently Asked Questions
What is the main difference between retatrutide and tirzepatide?
Tirzepatide activates two receptors (GIP and GLP-1). Retatrutide activates three (GIP, GLP-1 and glucagon). Tirzepatide is an approved medicine; retatrutide is still investigational.
Is retatrutide stronger than tirzepatide?
Published trials are not directly comparable because they used different populations, durations and designs. No head-to-head trial has reported. The key research difference is the glucagon component, not “strength”.
Is retatrutide approved in the UK?
No. Retatrutide is in Phase 3 trials and is not approved by the MHRA. It is available in the UK only as a research chemical.
Where can I read a deeper scientific comparison?
Our Tirzepatide vs Retatrutide research comparison covers mechanism and trial data in more depth.
All products supplied by Revial Labs are intended for in vitro laboratory research use only. They are not for human or veterinary use, and nothing in this article is medical advice or a recommendation for use in people or animals. Mounjaro is a registered trademark of Eli Lilly and Company.
